Dr. Zarifa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5145 N California Ave
Chicago, IL 60625Phone+1 773-878-8200Fax+1 773-293-5670
Summary
- I am an internal medicine resident at Brookdale Hospital University and Medical Center, graduated from Damascus University - Syria in 2016.
Worked at The University of Texas MD Anderson Cancer Center.
Education & Training
- Damascus University Faculty of MedicineClass of 2016
Certifications & Licensure
- IL State Medical License 2021 - 2026
- WI State Medical License 2024 - 2025
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.Mohamed A Gouda, Abdulrazzak Zarifa, Yali Yang, Bettzy Stephen, Serdar A Gurses
Journal of Immunotherapy and Precision Oncology. 2025-02-01 - 1 citationsA Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.Mohamed A Gouda, Bettzy Stephen, Yanyan Tian, Anas Alshawa, Dilichukwu O Chudy Onwugaje
Journal of Immunotherapy and Precision Oncology. 2024-11-01 - 5 citationsPhase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.Anne Knisely, Jibran Ahmed, Bettzy Stephen, Sarina A Piha-Paul, Daniel Karp
Cancer. 2024-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: